SCHEMBL29319332

SCHEMBL29319332

O=C(O)C12CC3CC(c4ccccc4)(CC(C1)C3CCF)C2

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.38
KDM4A O75164 3/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
KDM4B O94953 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
MAOB P27338 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29329737 0.92 HSD11B1 (0.37) HSD11B1LMNAALDH1A1KDM4AGRIN2D
SCHEMBL29319343 0.88 HSD11B1 (0.39) HSD11B1LMNAALDH1A1KDM4AGRIN2D
SCHEMBL29319169 0.87 HSD11B1 (0.39) HSD11B1LMNAALDH1A1GRIN2DGRIN3B
SCHEMBL29319306 0.86 LMNA (0.45) HSD11B1LMNAALDH1A1
SCHEMBL29319179 0.85 HSD11B1 (0.38) HSD11B1LMNAALDH1A1GRIN2DGRIN3B
SCHEMBL29329800 0.85 HSD11B1 (0.38) HSD11B1LMNAALDH1A1GRIN2DGRIN3B
SCHEMBL24139783 0.84 HSD11B1 (0.40) HSD11B1LMNAALDH1A1KDM4AGRIN2D
SCHEMBL29319356 0.84 HSD11B1 (0.41) HSD11B1LMNAALDH1A1GRIN2DGRIN3B
SCHEMBL29319139 0.80 ALDH1A1 (0.43) HSD11B1LMNAALDH1A1GRIN2DGRIN3B
SCHEMBL24139610 0.80 HSD11B1 (0.39) HSD11B1LMNAALDH1A1KDM4AGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2024-07-18 US disclosed
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2024-07-18 US disclosed
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION IFNAR1, NR4A3, NR0B2 HSD11B1 2165/4885LMNA 3555/4885ALDH1A1 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.